Status:
TERMINATED
Hereditary Angioedema Kininogen Assay
Lead Sponsor:
CENTOGENE GmbH Rostock
Conditions:
Hereditary Angioedema
Eligibility:
All Genders
18+ years
Brief Summary
A multicenter epidemiological observational study aiming to explore the cleaved high-molecular weight kininogen (cHMWK) including identification and characterization of other metabolite/biomarkers in ...
Detailed Description
Hereditary angioedema (HAE) is a rare autosomal dominant genetic disorder characterized by recurrent tissue angioedema episodes, mainly caused by mutations in the SERPING1 gene that encodes C1 inhibit...
Eligibility Criteria
Inclusion
- Informed consent is obtained from the participant
- The patient with diagnosis of Hereditary Angioedema (HAE) type 1/2 based on international guidelines
- The patient experienced ≥4 HAE attacks within last 12 month before enrolment in the study
- The participant is older than 18 years old
Exclusion
- Inability to provide informed consent
- The patient is not diagnosed with Hereditary Angioedema (HAE) type 1/2
- The patient experienced ˂ 4 HAE attacks within last 12 month before enrolment in the study
- The participant is younger than 18 years old
Key Trial Info
Start Date :
September 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT04091113
Start Date
September 1 2019
End Date
December 31 2021
Last Update
March 10 2022
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Charité - Universitätsmedizin Berlin
Berlin, Germany, 10117
2
Klinik für Hals-Nasen-Ohrenheilkunde, Universitätsklinikum Düsseldorf,
Düsseldorf, Germany, 40225
3
Klinikum der Johann-Wolfgang-Goethe-Universität
Frankfurt, Germany, 60596
4
Medizinische Hochschule Hannover
Hanover, Germany, 30625